JNJ-73841937 [Lazertinib], JNJ-61186372 [Amivantamab] clinical trials

A phase 2b, open-label, two-cohort study of subcutaneous amivantamab in combination with lazertinib as first-line treatment, or subcutaneous amivantamab in combination with platinum-based chemotherapy as second-line treatment, for common EGFR-mutated locally advanced or metastatic non-small cell lung cancer

This study looks at new drug combinations for a common type of lung cancer called NSCLC, specifically when it has a certain gene change (EGFR mutation). It tests if these new treatments can help reduce or slow down the cancer.